United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
United Therapeutics Corp. is conducting a Phase 3 study titled A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients. The study aims to assess the efficacy and safety of ralinepag, a drug intended to enhance treatment outcomes for patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH). This research is significant as it explores potential advancements in PAH treatment, which could improve patient quality of life.
The study tests ralinepag, an experimental drug administered in extended-release tablets, against a placebo. Ralinepag is designed to be added to the existing PAH standard of care or specific background therapy, aiming to delay clinical worsening events in patients.
This interventional study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. It employs quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose is treatment-focused, seeking to evaluate the time to clinical worsening events.
The study commenced on August 30, 2018, with an actual start date. The primary completion and estimated overall completion dates are not specified, but the latest update was submitted on June 23, 2025. These dates are crucial as they mark the progress and anticipated milestones of the study.
The outcome of this study could significantly impact United Therapeutics’ stock performance and investor sentiment, as successful results may enhance the company’s market position in the PAH treatment sector. Competitors in the PAH treatment industry will also be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.